Table 1.
Summary of Patient Characteristics Included in the 2 Modified Intention-to-Treat Populations (N = 131)
| Characteristic | Remdesivir | No Study Drug |
|---|---|---|
| No. of patients | 67 | 69 |
| Age, y, mean (SD) | 30.1 (8.2) | 30.1 (6.5) |
| Days since symptom onset, mean (SD) | 2.4 (0.8) | 2.2 (0.7) |
| Baseline viral load, log10 copies/mL, mean (range) | 5.5 (2.7–7.4) | 5.5 (3.0–7.9) |
| Vaccine doses received previously, median (range) | 3 (0–4) | 3 (0–4) |
| Antibody positive from rapid test, %a (Thailand only) | 90 | 94 |
| Male sex, % | 48 | 42 |
| Sites, No. | ||
| HTD | 54 | 57 |
| BP | 2 | 2 |
| VJ | 2 | 3 |
| UFMG | 9 | 7 |
Abbreviations: BP, Bangplee Hospital, Thailand; HTD, Hospital for Tropical Diseases, Thailand; SD, standard deviation; UFMG, Universidade Federal de Minas Gerais, Brazil; VJ, Vajira Hospital, Thailand.
aDefined as immunoglobulin M or immunoglobulin G present on the rapid antibody test (BIOSYNEX COVID-19 BSS IgM/IgG, Illkirch-Graffenstaden, France) used as per manufacturer's instructions.